BlackRock, Inc. ownership in OCX / OncoCyte Corporation

OncoCyte Corporation

US ˙ NasdaqCM ˙ US68235C2061

TEN SYMBOL NIE JEST JUŻ AKTYWNY

Security	OCX / OncoCyte Corporation
Institution	BlackRock, Inc.
Latest Disclosed Ownership	5,005,216 shares
Ownership	4.20%

2022-05-09 - BlackRock, Inc. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 5,005,216 shares of OncoCyte Corporation (US:OCX). This represents 4.2 percent ownership of the company. In their previous filing dated 2022-02-04 , BlackRock, Inc. had reported owning 4,993,146 shares, indicating an increase of 0.24 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2022-05-09	2022-05-09	13G	4,993,146	5,005,216	0.24	4.20	-22.22
2022-02-04	2022-02-04	13G	3,595,031	4,993,146	38.89	5.40	17.39
2021-02-10	2021-02-10	13G/A	3,502,031	3,595,031	2.66	4.60	-11.54
2021-02-02	2021-02-02	13G		3,502,031		5.20

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-13	2026-03-31	13F	INSIGHT MOLECULAR DIA	COM NEW	68235C206	135,345	3,984	3.03	444	-55.03	0.0000
2026-02-12	2025-12-31	13F	INSIGHT MOLECULAR DIA	COM NEW	68235C206	131,361	43,410	49.36	985	238.49	0.0000
2025-11-12	2025-09-30	13F	INSIGHT MOLECULAR DIA	COM NEW	68235C206	87,951	1,453	1.68	292	11.49	0.0000
2025-08-12	2025-06-30	13F	INSIGHT MOLECULAR DIA	COM NEW	68235C206	86,498	6,913	8.69	261	7.41	0.0000
2025-05-02	2025-03-31	13F	ONCOCYTE	COM NEW	68235C206	79,585	-372	-0.47	244	27.89	0.0000
2025-02-07	2024-12-31	13F	ONCOCYTE	COM NEW	68235C206	79,957	124	0.16	190	-16.30	0.0000
2024-11-13	2024-09-30	13F	ONCOCYTE	COM NEW	68235C206	79,833	7,006	9.62	228	6.07	0.0000
2024-08-13	2024-06-30	13F	ONCOCYTE	COM NEW	68235C206	72,827	12,640	21.00	215	21.59	0.0000
2024-05-10	2024-03-31	13F	ONCOCYTE	COM NEW	68235C206	60,187	0	0.00	176	17.33	0.0000
2024-02-13	2023-12-31	13F	ONCOCYTE	COM NEW	68235C206	60,187	-106	-0.18	150	-20.21	0.0000
2023-11-13	2023-09-30	13F	ONCOCYTE	COM NEW	68235C206	60,293	60,293		188		0.0000
2023-08-11	2023-06-30	13F	ONCOCYTE	COM	68235C107	1,212,026	-213,360	-14.97	279	-44.95	0.0000
2023-05-12	2023-03-31	13F	ONCOCYTE	COM	68235C107	1,425,386	6,978	0.49	505	10.99	0.0000
2023-02-13	2022-12-31	13F	ONCOCYTE	COM	68235C107	1,418,408	-886,923	-38.47	455	-72.95	0.0000
2022-11-14	2022-09-30	13F	ONCOCYTE	COM	68235C107	2,305,331	-38,095	-1.63	1,682	-20.21	0.0001
2022-08-12	2022-06-30	13F	ONCOCYTE	COM	68235C107	2,343,426	-2,590,223	-52.50	2,108	-71.32	0.0001
2022-05-12	2022-03-31	13F	ONCOCYTE	COM	68235C107	4,933,649	-59,497	-1.19	7,351	-32.15	0.0002
2022-02-10	2021-12-31	13F	ONCOCYTE	COM	68235C107	4,993,146	624,410	14.29	10,834	-30.34	0.0003
2021-11-09	2021-09-30	13F	ONCOCYTE	COM	68235C107	4,368,736	-360,990	-7.63	15,552	-42.72	0.0004
2021-08-11	2021-06-30	13F	ONCOCYTE	COM	68235C107	4,729,726	-238,488	-4.80	27,149	5.29	0.0008
2021-05-07	2021-03-31	13F	ONCOCYTE	COM	68235C107	4,968,214	1,466,183	41.87	25,784	208.02	0.0008
2021-02-05	2020-12-31	13F	ONCOCYTE	COM	68235C107	3,502,031	208,648	6.34	8,371	82.89	0.0003
2020-11-06	2020-09-30	13F	ONCOCYTE	COM	68235C107	3,293,383	694,768	26.74	4,577	-7.80	0.0002
2020-08-14	2020-06-30	13F	ONCOCYTE	COM	68235C107	2,598,615	1,033,049	65.99	4,964	29.44	0.0002
2020-05-01	2020-03-31	13F	ONCOCYTE	COM	68235C107	1,565,566	-21,439	-1.35	3,835	7.39	0.0002
2020-02-13	2019-12-31	13F	ONCOCYTE	COM	68235C107	1,587,005	-1,061	-0.07	3,571	7.08	0.0001
2019-11-08	2019-09-30	13F	ONCOCYTE	COM	68235C107	1,588,066	34,076	2.19	3,335	-13.80	0.0001
2019-08-22	2019-06-30	13F/A-1	ONCOCYTE	COM	68235C107	1,553,990	1,428,288	1,136.25	3,869	678.47	0.0002
2019-08-13	2019-06-30	13F	ONCOCYTE	COM	68235C107	1,553,990	1,428,288		3,869
2019-05-09	2019-03-31	13F	ONCOCYTE	COM	68235C107	125,702	59,556	90.04	497	446.15	0.0000
2019-02-08	2018-12-31	13F	ONCOCYTE	COM	68235C107	66,146	0	0.00	91	-45.18	0.0000
2018-11-09	2018-09-30	13F	ONCOCYTE	COM	68235C107	66,146	0	0.00	166	-1.78	0.0000
2018-08-09	2018-06-30	13F	ONCOCYTE	COM	68235C107	66,146	-139,041	-67.76	169	-60.79	0.0000
2018-05-09	2018-03-31	13F	ONCOCYTE	COM	68235C107	205,187	-1,986	-0.96	431	-55.29	0.0000
2018-02-09	2017-12-31	13F	ONCOCYTE	COM	68235C107	207,173	17,204	9.06	964	-32.82	0.0000
2017-11-14	2017-09-30	13F	ONCOCYTE	COM	68235C107	189,969	-7,730	-3.91	1,435	39.73	0.0001
2017-08-10	2017-06-30	13F	ONCOCYTE	COM	68235C107	197,699	116,192	142.55	1,027	111.75	0.0001
2017-05-12	2017-03-31	13F	ONCOCYTE	COM	68235C107	81,507	81,455	156,644.23	485	7,983.33	0.0000
2016-05-10	2016-03-31	13F	ONCOCYTE	COM	68235C107	52	52		0		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.